ArticleJournal of gastrointestinal oncology2015
HER2 expression in gastric and oesophageal cancer: a meta-analytic review.
Article in Journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- The value of the radiological diameter-to-thickness ratio in patients with HER2-positive resectable advanced gastric cancer: implications for long survival and stage migration.Abdominal radiology (New York) · 2024Article
- HER-2 positivity is a high risk of recurrence of stage I gastric cancer.The Korean journal of internal medicine · 2021Article
- Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020Review
- YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.Cancer science · 2020Article
- Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.Bioscience reports · 2020Article
- Article
- Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.Frontiers in oncology · 2017Article
- Basis for molecular diagnostics and immunotherapy for esophageal cancer.Expert review of anticancer therapy · 2017Review
- Article
- "Targeted" Chemotherapy for Esophageal Cancer.Frontiers in oncology · 2017Article
- Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2016Article
- Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma.TheScientificWorldJournal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the advent and the success of adjuvant medical therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the form of trastuzumab there has been increasing interest in the development of similar therapies in other solid organ malignancies including gastric cancer and oesophageal cancer. Over the years, multiple observational studies have been inconsistent. Several meta-analyses have been published looking at the association between HER2 and gastric cancer and oesophageal cancer. This review aims to summarize the meta-analytic evidence for the association between HER2 in gastric and oesophageal cancer.
methodsA systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane Library, Google Scholar, Science Direct, and Web of Science.
resultsOf the articles selected, only nine studies met full criteria. Six of them reviewed the role of HER2 in gastric cancer and the remaining three reviewed its role in oesophageal cancer.
conclusionsThe current evidence regarding the role of HER2 is unclear. However, it clearly plays a key role in the pathogenesis of gastric and oesophageal carcinomas. Targeted therapy towards this subgroup (despite variable frequency and association with survival) would offer a mortality benefit and improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.